stockrow
Friday 6 November 2026
Export CELC’s income statement to Excel — free account
Celcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
66.34
2.30
+3.59%
Follow CELC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 24 | 316 | 733 | +453.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (3) | (6) | (7) | (7) | (9) | (30) | (40) | (64) | (112) | (177) | (226) | +55.6% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (3) | (6) | (7) | (7) | (9) | (30) | (40) | (64) | (112) | (177) | (226) | +55.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.52) | (0.84) | (0.74) | (0.72) | (0.92) | (2.21) | (2.64) | (2.69) | (2.83) | (3.79) | (4.30) | +24.6% | ||||||
| Cash flow | (0.46) | (0.66) | (0.60) | (0.59) | (0.70) | (1.52) | (2.34) | (2.27) | (2.12) | (3.28) | (3.50) | +24.5% | ||||||
| Capex | (0.01) | (0.03) | (0.06) | (0.04) | (0.01) | (0.01) | (0.01) | 0.00 | (0.01) | (0.01) | (0.01) | (2.2%) | ||||||
| Free cash flow | (0.46) | (0.70) | (0.66) | (0.62) | (0.70) | (1.52) | (2.35) | (2.28) | (2.12) | (3.28) | (3.51) | +24.3% | ||||||
| Book value | 0.89 | 4.21 | 2.50 | 1.89 | 1.14 | 5.13 | 8.68 | 5.90 | 2.93 | 2.15 | (0.23) | +10.3% | ||||||
| Shares, m | 6 | 7 | 10 | 10 | 10 | 13 | 15 | 24 | 39 | 47 | 51 | +24.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (3) | (5) | (6) | (6) | (7) | (20) | (36) | (54) | (83) | (153) | (192) | +55.5% | |||||
| Capex | 0 | 0 | (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) | +22.2% | ||||||
| Free cash flow | (3) | (5) | (7) | (6) | (7) | (20) | (36) | (54) | (84) | (154) | (192) | +55.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 5 | 24 | 25 | 18 | 11 | 83 | 168 | 176 | 213 | 422 | 689 | +62.1% | |||||
| Net debt | (6) | (24) | (25) | (19) | (12) | (70) | (134) | (144) | (137) | (120) | (1) | +39.7% | ||||||
| Shareholders’ equity | 6 | 31 | 25 | 19 | 12 | 69 | 134 | 140 | 116 | 101 | (13) | +37.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (58.30) | (32.88) | (25.80) | (31.78) | (57.01) | (59.89) | (30.86) | (34.76) | (51.23) | (49.75) | (44.77) | +8.5 pt | |||||
| ROIC | 0.00 | (52.07) | (1,050.38) | (845.90) | (8,215.44) | 0.00 | (14,733.36) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (62.30) | (33.79) | (26.37) | (32.97) | (61.12) | (73.63) | (39.88) | (46.63) | (87.54) | (163.80) | (1,433.70) | (101.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 15 | 22 | 26 | 27 | 30 | 39 | 45 | 55 | 87 | 155 | — | +29.6% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Celcuity, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals, Inc. | $3.3B | — (loss-making) | — (loss-making) | +63.92% (above 0%: growing) | n/m | −144.14% (below 0%: shrinking) | 92.86% | (340.29%) | Compare |
| VKTX Viking Therapeutics, Inc. | $3.3B | — (loss-making) | — | — | n/m | −47.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ELVN Enliven Therapeutics, Inc. | $3.3B | — (loss-making) | — | — | n/m | −8.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DYN Dyne Therapeutics, Inc. | $3.2B | — (loss-making) | — | — | n/m | −39.08% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VRDN Viridian Therapeutics, Inc. | $3.2B | — (loss-making) | — (loss-making) | −63.51% (below 0%: shrinking) | n/m | −9.92% (below 0%: shrinking) | 100.00% | (401.82%) | Compare |
| TLX Telix Pharmaceuticals Limited | $3.2B | — | — | — | — | −44.78% (below 0%: shrinking) | — | — | Compare |
| DNLI Denali Therapeutics Inc. | $3.2B | — (loss-making) | — (loss-making) | −93.96% (below 0%: shrinking) | n/m | −11.83% (below 0%: shrinking) | 98.92% | (712.97%) | Compare |
| CELC Celcuity, Inc. | $3.1B | — (loss-making) | — | — | n/m | −53.27% (below 0%: shrinking) | 0.00% | 0.00% | |
| IDYA IDEAYA Biosciences, Inc. | $3.0B | — (loss-making) | — (loss-making) | −95.07% (below 0%: shrinking) | n/m | −165.94% (below 0%: shrinking) | 100.00% | (1,343.80%) | Compare |
| Median of peers | $3.2B | — | — | −78.73% | — | −41.93% | 92.86% | (340.29%) |
Pay and ownership Proxy statement filed 2 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 16.37m | 63.04m | 711.92 |
| 2024 | 6.59m | 5.20m | 93.43 |
| 2023 | 1.74m | 2.46m | 104.00 |
Ownership
Directors and executive officers, together
13.33%
Baker Bros. Advisors LP
19.99%
Brian F. Sullivan
8.62%
Perceptive Advisors LLC
6.54%
Avoro Capital Advisors LLC
6.44%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement